Header cover image

South Korean (KOSPI) Life Sciences Industry Analysis

UpdatedJan 19, 2022
DataAggregated Company Financials
Companies31
  • 7D-6.1%
  • 3M-5.8%
  • 1Y-1.2%
  • YTD-11.6%

Over the last 7 days, the Life Sciences industry has remained flat, although notably PHARMA RESEARCH BIO gained 12%. In line with that, the industry has also been flat over the past 12 months.

Industry Valuation and Performance

Has the South Korean Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPE
Wed, 19 Jan 2022₩60.6t₩2.3t₩412.7b25.3x
Fri, 17 Dec 2021₩71.5t₩2.3t₩412.7b29.5x
Sun, 14 Nov 2021₩62.0t₩2.1t₩329.9b25x
Tue, 12 Oct 2021₩61.9t₩2.1t₩329.9b26.2x
Thu, 09 Sep 2021₩68.8t₩2.2t₩330.9b36x
Sat, 07 Aug 2021₩69.5t₩2.2t₩336.8b35.5x
Fri, 30 Apr 2021₩62.1t₩2.1t₩247.5b38.5x
Mon, 01 Feb 2021₩61.2t₩2.0t₩213.0b58.3x
Thu, 05 Nov 2020₩52.3t₩1.8t₩306.1b36.4x
Sun, 09 Aug 2020₩55.1t₩1.7t₩273.1b72.6x
Sat, 02 May 2020₩42.6t₩1.4t₩209.9b69x
Tue, 04 Feb 2020₩35.2t₩1.2t₩177.8b60.5x
Fri, 08 Nov 2019₩29.3t₩1.0t₩180.2b73x
Thu, 01 Aug 2019₩21.4t₩994.5b₩154.3b54.5x
Sun, 05 May 2019₩26.2t₩1.0t₩159.7b62x
Wed, 06 Feb 2019₩29.5t₩1.0t₩154.2b40.8x
PE Ratio

40.8x

Total Market Cap: ₩29.5tTotal Earnings: ₩154.2bTotal Revenue: ₩1.0t0%0%0%3 Year10 Year
202020212022

Current Industry PE: Investors are more pessimistic on the industry, considering it's trading at a PE ratio of 26.3x which is lower than its 3-year average PE of 52.7x. It appears they believe that earnings will not grow as fast as they have historically.

Past Earnings Growth: The earnings for companies in the Life Sciences industry have grown 39% per year over the last three years, and revenues for these companies have grown 32% per year. This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the South Korean Life Sciences industry?

Clinical Research and Equipment-6.12%

Industry PE: Investors are most optimistic about the Clinical Research and Equipment industry even though it's trading below its 3-year average PE ratio of 52.7x. This is likely because analysts are expecting annual earnings growth of 17%, which is higher than its past year's earnings growth of 15% per year.

Forecasted Growth: Analysts are most optimistic on the Clinical Research and Equipment industry, expecting annual earnings growth of 17% over the next 5 years. This is roughly in line with its past earnings growth rate.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
A217950 PHARMA RESEARCH BIO₩32.90k9.1%
+₩11.1b
128.5%n/a
A281310 Bio-Synectics₩8.20k2.5%
+₩527.0m
23.1%n/a
A258540 StemLab₩5.19k2.0%
+₩521.4m
-8.4%n/a
A266470 BioInfra Life Science₩2.35k0.4%
+₩140.9m
-17.1%n/a
Simply Wall St
Simply Wall Street Pty Ltd
17-21 Bellevue Street, Surry Hills, Sydney
Download on the App StoreGet it on Google Play
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News